Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer
There is mounting evidence that the immune system can spontaneously clear malignant lesions before they manifest as overt cancer, albeit this activity has been difficult to demonstrate in humans. The calreticulin ( CALR ) exon 9 mutations are driver mutations in patients with chronic myeloproliferat...
Gespeichert in:
Veröffentlicht in: | Cancer Immunology, Immunotherapy Immunotherapy, 2020-02, Vol.69 (2), p.315-324 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | There is mounting evidence that the immune system can spontaneously clear malignant lesions before they manifest as overt cancer, albeit this activity has been difficult to demonstrate in humans. The calreticulin (
CALR
) exon 9 mutations are driver mutations in patients with chronic myeloproliferative neoplasms (MPN), which are chronic blood cancers. The
CALR
mutations generate a neo-antigen that is recognized by patient T cells, and T cells isolated from a patient with a
CALR
-mutation can recognize and kill autologous
CALR
-mutant cells. Surprisingly, healthy individuals display frequent and strong T cell responses to the CALR neo-antigens too. Furthermore, healthy individuals display immune responses to all parts of the mutant CALR epitope, and the CALR neo-epitope specific responses are memory T cell responses. These data suggest that although healthy individuals might acquire a
CALR
mutation, the mutant cells can be eliminated by the immune system. Additionally, a small fraction of healthy individuals harbor a
CALR
exon 9 mutation. Four healthy individuals carrying
CALR
mutations underwent a full medical examination including a bone marrow biopsy after a median follow up of 6.2 years. None of these patients displayed any signs of
CALR
-mutant MPN. Additionally, all healthy individuals displayed strong CALR neo-epitope specific T cell responses suggesting that these healthy individuals retained their
CALR
-mutant cells in the editing stage for several years. Thus, we suggest that
CALR
-mutant MPN could be a disease model of cancer immuno-editing, as we have demonstrated that
CALR
-mutant MPN displays all three stages described in the theory of cancer immuno-editing. |
---|---|
ISSN: | 0340-7004 1432-0851 |
DOI: | 10.1007/s00262-019-02473-y |